Interpore Cross International
This article was originally published in The Gray Sheet
Executive Summary
Firm's Pro Osteon 500 bone graft substitute gains FDA approval for expanded indications in treating cysts and tumors in long bones, both in the metaphysis and the diaphysis. The expanded approval via premarket approval application supplement now allows the firm's domestic sales force, which includes direct reps and agents, to promote Pro Osteon to the orthopedic surgical oncologist, the firm says. The product was approved in October 1992 for use in acute, metaphyseal long bone fractures ("The Gray Sheet" Nov. 9, 1992, I&W-4)...